PDB - 5X8L: PD-L1 in complex with atezolizumab, (312K, 39°C, 100 ns): RMSD, SASA, RMSF, Rg, H-bonds
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
PDB - 5X8L: PD-L1 in complex with atezolizumab, (312K, 39°C, 100 ns): RMSD, SASA, RMSF, Rg, H-bonds
应用场景：
创建时间：
2024-07-10
相关数据集
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
The precise incidence of immune-related adverse events (irAEs) remains unclear. This pharmacovigilance study investigated acute pancreatitis (AP) associated with immune checkpoint inhibitors (ICIs) us
Figshare2025-03-28 更新60
Data_Sheet_1_Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.zip
Purpose: Drug-induced fever is frequently reported in cancer patients treated with anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), and stoppage of the offending agent is th
NIAID Data Ecosystem40
Table 4 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
Specific irAEs experienced by patients with and without ICI-related fatigue.
NIAID Data Ecosystem30
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
The precise incidence of immune-related adverse events (irAEs) remains unclear. This pharmacovigilance study investigated acute pancreatitis (AP) associated with immune checkpoint inhibitors (ICIs) us
DataCite Commons2025-05-14 更新60
Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer Patients
Pruritus is the main symptom associated with immune-related adverse events and can significantly impact the patient's quality of life and adherence to antineoplastic treatment. Omalizumab has shown po
NIAID Data Ecosystem30
